%0 Journal Article
%T Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
%A Andrea L Ciaranello
%A Ashraf Coovadia
%A D¨¦sir¨¦ L Dahourou
%A Elaine J Abrams
%A Kenneth A Freedberg
%A Louise Kuhn
%A Madeleine Amorissani-Folquet
%A Martina Penazzato
%A Renate Strehlau
%A Rochelle P Walensky
%A Simone C Frank
%A Sophie Desmonde
%A Taige Hou
%A Valeriane Leroy
%J Archive of "Open Forum Infectious Diseases".
%D 2019
%R 10.1093/ofid/ofz276
%X The NEVEREST-3 (South Africa) and MONOD-ANRS-12206 (C£¿te d¡¯Ivoire, Burkina Faso) randomized trials found that switching to efavirenz (EFV) in human immunodeficiency virus¨Cinfected children >3 years old who were virologically suppressed by ritonavir-boosted lopinavir (LPV/r) was noninferior to continuing o LPV/r. We evaluated the cost-effectiveness of this strategy using the Cost-Effectiveness of Preventing AIDS Complications¨CPediatric model
%K Africa
%K cost-effectiveness
%K HIV
%K pediatrics
%K treatment strategies
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634435/